What changed
$PAYX — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ3 FY2020 (ends May) | reported Jun 24 | Rev $1.8B | EPS $1.32 vs $1.31 🟢 | Margin 45.2%
💡 Consensus sees steady growth, but the tiny earnings beat (+0.8%) doesn't warrant a re-rating. The market is pricing in business as usual, while the risk of multiple compression to bear-case levels is not reflected.
🏢 Business Quality: 7/10
📊 Valuation: fair
🔮 Catalyst: Next quarterly earnings report
⚖️ Avoid: 0.4:1 reward/risk, bottom 1% quant rank, and negligible earnings beat offer no edge for longs.